Skip to content

Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block

Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Patient Undergoing Breast Cancer Surgery :A Comparative Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03063073
Acronym
pec's
Enrollment
60
Registered
2017-02-24
Start date
2017-02-25
Completion date
2017-06-15
Last updated
2026-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Female

Brief summary

The Pecs block (pectoral nerves block) is an easy and reliable superficial block inspired by the infraclavicular block approach and the intercostal abdominis plane blocks . Many additives were used in combination with local anesthetics in Pecs block to prolong the postoperative analgesia (fentanyl, dexmedetomidine).

Detailed description

60 patients scheduled for modified radical mastectomy surgery under general anesthesia. Group I (Bupivacaine group): patients underwent modified radical mastectomy were given preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles on the interfascial plane, and 20 ml injected between the Pectoralis minor muscle and the serratus muscle.Group II (Bupivacaine + Dexmedetomidine group) : preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg) divided into 20 ml injected between the pectoralis muscles on the interfascial plane , and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.

Interventions

DRUGDexmedetomidine Injection [Precedex]

ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection \[Precedex\]

ultrasound guided modified Pec's block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscl

Sponsors

South Egypt Cancer Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* ASA I - II patients * weight 50- 100 kg * age 18-60 years

Exclusion criteria

* History of bleeding diathesis * Relevant drug allergy * Opioid dependence * Sepsis * Those with psychiatric illnesses that would interfere with perception and assessment of pain will be excluded from the study

Design outcomes

Primary

MeasureTime frameDescription
I.V patient controlled analgesia (PCA) morphine consumption48 hours postoperativethe total dose of I.V patient controlled analgesia (PCA) morphine consumption in the first 48 hours postoperative

Secondary

MeasureTime frameDescription
pain relief48 hourby visual analogue scale measurement

Countries

Egypt

Contacts

STUDY_DIRECTORsahar m abd elbaqy, professor

manager

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026